Neuroanesthesia & neurocritical care
Dexmedetomidine administration during brain tumour resection for prevention of postoperative delirium: a randomised trial
Primary resultResult — go to the resultRelative risk 0.51 95% CI 0.36–0.74Authors' conclusion
Prophylactic intraoperative dexmedetomidine infusion reduced by half the incidence of delirium during the initial 5 postoperative days in patients recovering from elective brain tumour resection.
Study context
- Population
- Patients undergoing intracerebral tumour resection, two tertiary-care hospitals in Beijing
- Participants
- 260 patients
- Comparison
- Intraoperative dexmedetomidine vs placebo
- Dexmedetomidinen = 130
- Placebon = 130reference
- Primary endpoint
- Incidence of delirium (Confusion Assessment Method twice daily)
- Follow-up
- Initial 5 postoperative days
Methodological detailsdouble-blind, placebo-controlled, two tertiary-care hospitals
- Double-blind
- Placebo-controlled
- Two tertiary-care hospitals
Primary result
As reported in the abstract
Relative risk
0.51
95% CI 0.36–0.74
P < 0.001
Events by treatment group
Dexmedetomidine vs Placebo
RR 0.51 (95% CI 0.36–0.74); P < 0.001
Further findings
Postoperative pain scores with movement, recovery and sleep quality
- Improved by dexmedetomidine
- P < 0.001
Safety
Safety outcomes
- Incidence similar in each group
Original publication
Dexmedetomidine administration during brain tumour resection for prevention of postoperative delirium: a randomised trial. Br J Anaesth. Published 13 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →